Q1 2025 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2025-05-15 · accession 0001104659-25-049390
$111.1M
Reported value
5
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $69.2M | 62.3% | 4,410,581 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics Inc | $23.3M | 20.9% | 2,111,919 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $8.6M | 7.75% | 16,007,999 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $7.3M | 6.61% | 1,111,882 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $2.6M | 2.36% | 1,000,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.